hVIVO (HVO.L, HVO LN)
- 155.8
- 680.4
- 91.3
Company Profile
hVIVO is a European CRO focussed on providing pre-clinical and clinical trial services to pharma, biotech and medtech clients. It is the world leader in conducting human challenge trials. It is the only CRO focused on challenge studies providing world class expertise and capabilities in challenge agent manufacture, a unique portfolio of established human challenge models to test a broad range of infectious and respiratory disease products, and specialist drug development and clinical consultancy services. It can assist in clinical trial site selection, investigator and patient recruitment, study design, trials management, data management and analysis, and regulatory affairs. It also provides laboratory services for customers where it provides high quality sample analysis and data outputs.
Major Shareholders | % |
Octopus Investments Ltd. | 12.3 |
JPMorgan Asset Mgt. (UK) Ltd. | 7.0 |
Canaccord Genuity Wealth Ltd. | 4.0 |
Friel Cathal Martin | 3.1 |
Rankin Allan | 3.0 |